Drug Pipeline

FDA Updates: Ofatumumab for MS, More Data Needed for Filgotinib in RA, Hearing Set for ALKS 3831

August 23, 2020

FDA actions for the week ending August 21, 2020, include a hearing set for a drug that could limit weight gain often associated with treatment for serious mental illness.

FDA Updates: Treatment for Duchenne Mutation, Gilead Seeks Remdesivir Approval, Data on ALKS 3831

August 16, 2020

Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.

FDA Updates: Blood Cancers, Orphan Drug Designations Get Priority

August 02, 2020

In a busy week, FDA approved ground-breaking therapies in hematologic cancers and issued Orphan Drug designations in areas of significant unmet need.

New Drugs Take Aim at Autoimmune Diseases

July 31, 2020

Potential agents to battle inflammation and other processes move through development pipeline.

Our Coverage of the Race to Develop a COVID-19 Vaccine

July 29, 2020

As several COVID-19 vaccine candidates are now in the late phase of clinical trials, MHE is sharing a few stories that have covered the infamous virus' vaccine development journey.

Sandoz, Boehringer Ingelheim Battle Biosimilar Misinformation

July 24, 2020

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

Famed AIDS Researcher Finds That the Sickest Patients Could Hold the Key to Beating COVID-19

July 23, 2020

Dr. David Ho, who developed the HIV cocktail, has isolated antibodies he says could be used to create treatments for COVID-19.

How Will Real-World Evidence Help Drive Solutions for COVID-19?

July 19, 2020

How real-world evidence will help FDA develop a vaccine.

It's Possible for Those Who Practice, Pay for Precision Oncology to Catch Up to Speed of Innovation

July 14, 2020

The fast-evolving field of precision medicine offers the promise of more effective treatments and better outcomes, and it’s time that we collaborate to keep outdated clinical and reimbursement practices from slowing it down.